Navigation Links
Deloitte Recap Launches New Solution for Clinical Development
Date:11/11/2009

SAN FRANCISCO, Nov. 11 /PRNewswire/ -- Deloitte Recap LLC (Recap) has launched "Development Optimizer," the third product in the Recap IQ Series by Deloitte. The series of biopharmaceutical business intelligence tools are part of a new subscription service tailored toward business development, corporate strategy, financial, clinical development, legal, academic and R&D professionals.

"Development Optimizer" provides flexible analytical tools for biopharmaceutical executives making portfolio decisions and offers subscribers new ways to look at attrition, development and regulatory performance and termination efficiency. Subscribers gain access to a groundbreaking tool built on Recap's richly detailed clinical and regulatory histories for the Recap BioPortfolio Index (RBI). The RBI is a select group of more than 150 biotechnology companies Recap has tracked and benchmarked for more than a decade.

"Development Optimizer uniquely captures the complete clinical development histories of these companies, allowing users the ability to see the big picture, while also being able to drill down to the pertinent details often not available to the public," said Mark Edwards, the managing director of Deloitte Recap LLC. "It supports strategic decision-making and best practice adoption among clinical development professionals providing searchable data at all stages of drug development."

Development Optimizer provides the underlying data for the analyses. Attrition Analysis graphs the number and percentage of projects or compounds that terminated at each phase of development for any chosen data set. Users have the ability to run comparative analyses of attrition rates by therapeutic area, indication, mechanism of action, and technology and then examine the supporting detail behind the graphs to understand why projects terminated.

"Deloitte Recap's proprietary analytical approach, combined with a detailed tracking of key regulatory designations and events, from Investigational New Drug (IND) filing dates to FDA 'Fast Track' and orphan drug status designations, allows subscribers to examine drug development information in an entirely new way," added Matthew Hudes, a principal with Deloitte Consulting LLP. "Subscribers can compare data from successful compounds, as well as understand the reasons behind termination across each phase of development, by clinical or therapeutic area, providing an industry benchmark for how successful companies were able to achieve FDA approval and speed up time to market, as well as learning from the compounds that failed."

Development and Regulatory Analysis compares clinical development time to FDA regulatory review time to better understand how quickly companies have successfully gotten their products approved. Termination Efficiency Analysis examines how efficiently companies have made key "go" or "no-go" drug development decisions. Development Optimizer's detailed supporting documentation includes interactive compound development timelines, clinical trial design, press releases, abstracts and regulatory records.

Development Optimizer is the third product within the new Recap IQ Series by Deloitte, which provides analytical tools to help Life Sciences companies leverage biopharma alliance data, deal values and drug development histories to support the development of alliance and clinical development strategies. The first two complementary modules, "Deal Builder" and "Valuation Analyzer," launched earlier this month. "Deal Builder" is a comprehensive, fully searchable database of 30,000 biopharma and related alliances covering the past three decades, including 24,000 U.S. Securities and Exchange Commission-filed contracts. "Valuation Analyzer" provides access to the Recap Effective Royalty Rate (EFR) Grapher, a tool used to perform real-time searches of more than 1,500 unredacted biopharma alliances with fully disclosed SEC-filed contracts to analyze effective royalty rates for deal by stage of development at signing.

"Given the pace of today's rapidly changing biopharmaceutical industry, the Recap IQ Series by Deloitte provides a much needed source for real-time data based on business intelligence to help subscribers make informed strategic decisions, from M&A and alliance formation to clinical development decisions," added Jacques Mulder, a principal with Deloitte Consulting LLP.

About Recap

Originally founded as Recombinant Capital, Inc. in 1988 by Mark Edwards and based in the San Francisco Bay Area. In July 2008, Recombinant Capital, Inc. was purchased by a subsidiary of Deloitte LLP and the business is now known as Deloitte Recap LLC (Recap). Please see www.recap.com for more information about Recap's services. As used in this document, "Recap" means Deloitte Recap LLC and "Deloitte" means Deloitte LLP and Deloitte Services LP, a subsidiary of Deloitte LLP. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries.

SOURCE Deloitte


'/>"/>
SOURCE Deloitte
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region
2. Accuray Ranked 155th Fastest Growing Company in North America on Deloittes 2009 Technology Fast 500(TM)
3. Advanced Health Media Named to Deloittes 2009 Technology Fast 500(TM)
4. Deloitte Report: Pharmaceutical Companies Patent Cliff Could Bolster Mergers and Acquisitions
5. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
6. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
7. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
8. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
9. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
10. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
11. Premier Micronutrient Launches Supplement for Hearing Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Eli Lilly and ... the neoMONARCH study of abemaciclib, a cyclin-dependent kinase (CDK) ... of reducing expression of Ki67, a biomarker of cell ... the Phase 2 trial presented during the official press ... (SABCS) evaluated abemaciclib, both alone or in combination with ...
(Date:12/7/2016)... Global Cervical Dysplasia Market: Scope and ... dysplasia market analyzes the current and future prospects ... executive summary, including a market snapshot that provides ... The research is a combination of primary and ... our research efforts along with information collected from ...
(Date:12/7/2016)... REPORT OBJECTIVES The report ... intelligence on a market segment, based on geography. ... in the report. The primary objectives of this ... intelligence through detailed segmentation, 2) market size and ... developments, market situation, trends, 3) detailed analysis of ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Children exposed to secondhand marijuana ... the Icahn School of Medicine at Mount Sinai has found. The study was ... children are exposed to secondhand marijuana smoke, measurable amounts of primary metabolite of ...
(Date:12/7/2016)... ... December 07, 2016 , ... Wavelink, ... Device Remote Control through a new partnership with Splashtop Inc. This remote control ... mobile solutions to help businesses maximize their uptime and productivity. , Wavelink offers ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... S.L. (“Presence”) for a purchase price of approximately $17.4 million (net of ... annual revenue is approximately $13.2 million. Headquartered in Barcelona, Spain, Presence is ...
(Date:12/7/2016)... Yorba Linda, Ca (PRWEB) , ... December 07, 2016 , ... ... to attain that funding is with useful, properly analyzed data. The team at Beckman ... generation to address the 'need for speed' and the need to operate in a ...
(Date:12/7/2016)... ... 2016 , ... A quote from Dr. Edward Hallowell, host of CRN International’s ... offer a rare glimpse into the mind of those people with ADHD. , Dr. ... author, has described people with ADHD as having “Ferrari engines for a brain, with ...
Breaking Medicine News(10 mins):